Below is a selection of our recent papers and poster presentations. If you would like to discuss how the cell microarray technology could be applied in your research please get in touch.

Mining naïve rabbit antibody repertoires by phage display for monoclonal antibodies of therapeutic utility

Peng H, Nerreter T, Chang J, Qi J, Li X, Karunadharma P, Martinez G, Fallahi M, Soden J, Freeth J, Beerli RR & Grawunder U.

Journal of Molecular Biology 2017 (in press). View the abstract and full article options online here

Specificity screening of antibodies and related molecules using human cell microarray technology

Kingsley E, Freeth J, Soden J

Poster presentation PEGS Boston 2017 – download pdf

Nonclinical safety assessment in cancer immunotherapy: Off-target profiling of whole CAR T cells using plasma membrane protein arrays

Freeth J, Soden J, Bourdeau A, Rottman J, Kasperkovitz P, Friedman K, Horvath C

Poster presentation SOT 2017 – download pdf

Identification of human junctional adhesion molecule-1 as a functional receptor for the Hom-1 calicivirus on humans cells

Stanislav V. Sosnovtsev, Carlos Sandoval-Jaime, Gabriel I. Parra, Christine M. Tin, Ronald W. Jones, Jo Soden, Donna Barnes, Jim Freeth, Alvin W. Smith, Kim Y. Green

mBio 2017; 8:1 – View the full, open access article at

Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy

Geoffrey S. Williams, Bina Mistry, Sandrine Guillard, Jane Coates Ulrichsen, Alan M. Sandercock, Jun Wang, Andrea González-Muñoz, Julie Parmentier, Chelsea Black, Jo Soden, Jim Freeth, Jelena Jovanović, Rebecca Leyland, Rafia S. Al-Lamki, Andrew J. Leishman, Steven J. Rust, Ross Stewart, Lutz Jermutus, John R. Bradley, Vahe Bedian, Viia Valge-Archer, Ralph Minter, Robert W. Wilkinson


Oncotarget 2016 7:68278-68291 (DOI: 10.18632) – View the full open-access article online here.

A powerful approach to uncover immune checkpoint receptors using human plasma membrane  protein arrays (PMPA)

Freeth J, Dawson S, Barnes D, Thomas H, Kingsley E & Soden J


Poster presentation PEGS Boston 2016 – download pdf

Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling

Alan M. Sandercock, Steven Rust, Sandrine Guillard, Kris F. Sachsenmeier, Nick Holoweckyj, Carl Hay, Matt Flynn, Qihui Huang, Kuan Yan, Bram Herpers, Leo S. Price, Jo Soden, Jim Freeth, Lutz Jermutus, Robert Hollingsworth and Ralph Minter


Molecular Cancer 2015, 14:147 – View the full open-access article online here.

Targeting human cancer by a glycosaminoglycan binding malaria protein

Ali Salanti, Thomas M. Clausen, Mette Ø. Agerbæk, Nader Al Nakouzi, Madeleine Dahlbäck, Htoo Z. Oo, Sherry Lee, Tobias Gustavsson, Jamie R. Rich, Bradley J. Hedberg, Yang Mao, Line Barington, Marina A. Pereira, Janine LoBello, Makoto Endo, Ladan Fazli, Jo Soden, Chris K. Wang, Adam F. Sander, Robert Dagil, Susan Thrane, Peter J. Holst, Le Meng, Francesco Favero, Glen J. Weiss, Morten A. Nielsen, Jim Freeth, Torsten O. Nielsen, Joseph Zaia, Nhan L. Tran, Jeff Trent, John S. Babcook, Thor G. Theander, Poul H. Sorensen, Mads Daugaard


Cancer Cell 2015, 28(4):500-14 – View the abstract and full article options online here

Severe malaria is associated with parasite binding to endothelial protein C receptor

Louise Turner, Thomas Lavstsen,  Sanne S. Berger, Christian W. Wang, Jens E. V. Petersen, Marion Avril, Andrew J. Brazier, Jim Freeth, Jakob S. Jespersen, Morten A. Nielsen, Pamela Magistrado, John Lusingu, Joseph D. Smith, Matthew K. Higgins & Thor G. Theander


Nature 2013, 498:502 – View the full study online at

The University of Sheffield
Aveo Oncology - The Human Response
Theraclone Sciences
Bluebird Bio
The Center for Infectious Disease Research
Compugen Logo
The University of Copenhagen
Lund University
NIH - National Institutes of Health
The University of Pennsylvania
Scripps Florida - The Scripps Research Institute
Peptinnovate Ltd - Unlocking Nature's Potential
We were impressed with the power of the Retrogenix technology in terms of on/off target characterization of early drug candidates. Their quick turnaround time and excellent, proactive communication was a real pleasure.
Dr. Bernd Schlereth, Senior Director Nonclinical Safety, Covagen